NUVECTIS PHARMA INSIDER BUYING SURGE: Finance VP’s $0‑Priced Restricted Shares Signal Confidence Amid Pipeline Momentum and Market Volatility
Carson Michael J.’s insider buying at Nuvectis Pharma—zero‑price restricted shares—signals executive confidence in the biopharma’s growth, yet highlights the company’s high‑risk, late‑stage drug pipeline and recent market volatility.
3 minutes to read
